EYLEA® Proposed Biosimilar M710 BPCIA Appeals Dismissed For Lack Of Jurisdiction - Patent

On April 12, 2024, the Federal Circuit dismissed CAFC Appeal No. 24-1402 and Cross-Appeal No. 24-1405 for lack of jurisdiction following its February 22, 2024 order directing Regeneron and Mylan / Biocon.

Related Keywords

Formycon Klinge Biopharma ,Mylan Biocon ,April Breyer Menon ,Biocon ,District Court ,Federal Circuit ,Klinge Biopharma ,Samsung Bioepis ,Mondaq ,Eylea Xae Proposed Biosimilar M710 Bpcia Appeals Dismissed For Lack Of Jurisdiction ,Food ,Drugs ,Healthcare ,Life Sciences ,Iotechnology Amp Nanotechnology ,Intellectual Property ,Patent ,Litigation ,Ediation Amp Arbitration ,Trials Amp Appeals Compensation , ,